Spyre Therapeutics, Inc. (SYRE)
72.19
+0.19
(+0.26%)
USD |
NASDAQ |
Jun 09, 13:16
Spyre Therapeutics SG&A Expense (Quarterly) : 15.23M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Praxis Precision Medicines, Inc. | 27.87M |
| Viridian Therapeutics, Inc. | 38.68M |
| Relay Therapeutics, Inc. | 11.03M |
| Damora Therapeutics, Inc. | 7.034M |
| Savara, Inc. | 15.57M |